Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates
US6099846A · kind A · utility
6Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 14, 1995 |
| Grant date | Aug 8, 2000 |
| Priority date | — |
| Expiry date | Apr 14, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
B cell lymphoma tumor-associated antigen or a fragment thereof containing an epitope are linked to an immune-enhancing cytokine, such as GM-CSF, IL-2, or IL-4 to form an immuno-complex. This immuno-complex elicits immune responses which are protective with respect to tumor proliferation. The linkers may be simple chemical bifunctional moieties introduced through chemical synthetic techniques or peptides introduce through recombinant methodologies. Antibodies immunoreactive with these immunocomplexes are also useful as passive vaccines and as analytical tools.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.